

1 **Title:** Longitudinal detection of SARS-CoV-2-specific antibody responses with different
2 serological methods

3 **Running head:** Kinetics of anti-SARS-CoV-2 antibodies

4 **Authors:** Petra Emmerich^{1,2}, Ronald von Possel^{1,2}, Christoph Josef Hemmer², Carlos Fritzsche²,
5 Hilte Geerdes-Fenge², Babett Menge³, Claudia Messing³, Viola Borchardt-Lohölter^{3,*}, Christina
6 Deschermeier⁴⁺, Katja Steinhagen³⁺

7 **Affiliations:**

8 ¹ Department of Virology, Bernhard Nocht Institute for Tropical Medicine, WHO Collaborating Centre
9 for Arbovirus and Hemorrhagic Fever Reference and Research, Hamburg, Germany

10 ² Department of Tropical Medicine and Infectious Diseases, Center for Internal Medicine, University of
11 Rostock, Rostock, Germany

12 ³ Institute for Experimental Immunology, affiliated with EUROIMMUN Medizinische Labordiagnostika
13 AG, Luebeck, Germany

14 ⁴ Department for Infectious Disease Diagnostics, Bernhard Nocht Institute for Tropical Medicine,
15 Hamburg, Germany

16 * Corresponding author: Viola Borchardt-Lohölter, EUROIMMUN Medizinische Labordiagnostika AG,
17 Seekamp 31, 23560 Luebeck, Germany, v.borchardt-lohoelter@euroimmun.de, +49 451 20321619.

+ These authors contributed equally.

18 **Keywords:** antibodies, COVID-19, ELISA, immunofluorescence, SARS-CoV-2, serology

19 **ABSTRACT**

20 Serological testing for anti-SARS-CoV-2 antibodies is used to detect ongoing or past SARS-CoV-2
21 infections. To study the kinetics of anti-SARS-CoV-2 antibodies and to assess the diagnostic
22 performances of eight serological assays, we used 129 serum samples collected on known days
23 post symptom onset (dpso) from 42 patients with PCR-confirmed COVID-19 and 54 serum
24 samples from healthy blood donors, and children infected with seasonal coronaviruses.

25 The sera were analyzed for the presence of IgG, IgM and IgA antibodies using indirect
26 immunofluorescence testing (IIFT) based on SARS-CoV-2-infected cells. They were further
27 tested for antibodies against the S1 domain of the SARS-CoV-2 spike protein (IgG, IgA) and
28 against the viral nucleocapsid protein (IgG, IgM) using ELISA.

29 The assay specificities were 94.4%-100%. The sensitivities varied largely between assays,
30 reflecting their respective purposes. The sensitivities of IgA and IgM assays were highest
31 between 11 and 20 dpso, whereas the sensitivities of IgG assays peaked between 20 and 60
32 dpso.

33 IIFT showed highest sensitivities due to the use of the whole SARS-CoV-2 as substrate and
34 provided information whether or not the individual has been infected with SARS-CoV-2. ELISAs
35 provided further information about both the prevalence and concentration of specific antibodies
36 against selected antigens of SARS-CoV-2.

37 INTRODUCTION

38 In the current pandemic, direct pathogen detection via reverse transcription and polymerase
39 chain reaction amplification as well as real-time detection (real-time RT-PCR) is the gold
40 standard for SARS-CoV-2 detection and enables early identification of acute SARS-CoV-2
41 infections. Serological testing for anti-SARS-CoV-2 antibodies is used to confirm ongoing or past
42 infections with SARS-CoV-2. The detection of antibodies enables confirmation of SARS-CoV-2
43 infection in patients with typical symptoms and in suspected (asymptomatic) cases. Analysis of
44 anti-SARS-CoV-2 antibodies is typically performed at an advanced stage of infection and thus
45 expands the time frame for COVID-19 diagnostics.

46 Seroconversion of anti-SARS-CoV-2 antibodies can occur at different points in time after virus
47 contact^{1,2}. The features of immune responses to SARS-CoV-2 infections vary significantly
48 between individuals³, especially regarding the kinetics, immunoglobulin classes and antigen
49 specificity. In the majority of COVID-19 patients, anti-SARS-CoV-2 antibodies are detectable
50 within two weeks of infection⁴⁻⁶. Usually, specific IgM and IgA antibodies are detectable earlier
51 than specific IgG antibodies^{5,7,8}. In individual cases, anti-SARS-CoV-2 antibodies are either only
52 detectable more than four weeks after onset of symptoms or not at all due to generally absent
53 antibody secretion⁸⁻¹⁰.

54 Anti-SARS-CoV-2 antibodies target different structural proteins of SARS-CoV-2. The main
55 immunogens are the spike and nucleocapsid proteins. The highly immunogenic S1 domain of the
56 spike protein of SARS-CoV-2 is a major target for neutralizing antibodies and is being used as the
57 antigen in many serological assays¹¹. The immunologically relevant receptor binding domain
58 (RBD) represents another important target antigen for virus-neutralizing antibodies¹². The
59 nucleocapsid protein (NCP) of SARS-CoV-2 is the antigen with the strongest immune dominance
60 among *Coronaviridae*¹³ and contains diagnostically relevant epitopes of SARS-CoV-2. Previous
61 studies suggested heterogeneous binding antibody responses to S1/RBD and NCP viral
62 antigens¹⁴, and hence the presence of antibodies against one protein of SARS-CoV-2 does not
63 necessarily coincide with the presence of antibodies against another.

64 Current research is determined to illuminate kinetics of the humoral immune response against
65 SARS-CoV-2, potentially providing guidance on when to use serological tests effectively for
66 screening or monitoring of the infection. Results of serological tests can provide answers to
67 important epidemiological, clinical and virological questions concerning SARS-CoV-2, for
68 instance, on the traceability of infection chains and the role of asymptomatic or presymptomatic
69 transmission. Moreover, exact determination of the course of concentration of IgG antibodies
70 against SARS-CoV-2 before and after vaccination can provide valuable information on the
71 effectiveness of vaccination.

72 Currently, knowledge about SARS-CoV-2 antibody persistence is scarce, although it would help
73 to understand the possible role of humoral immunity in the protection against reinfection. The
74 aim of this research was to study the kinetics of antibodies against SARS-CoV-2 and to explore
75 the characteristic features of eight serological assays.

76 METHODS

77 Human serum samples

78 Panel A comprised 82 sequential and single serum samples from 25 German patients (Table 1).
79 Infection with SARS-CoV-2 was confirmed by PCR¹⁵ by regional health authorities. These
80 patients had mild to moderate COVID-19 symptoms.

81 Panel B comprised 47 sequential and single serum samples from 17 German patients (Table 1).
82 Infection with SARS-CoV-2 was confirmed by PCR using the Allplex 2019-nCoV Assay (Seegene
83 Inc., Seoul, Korea). These patients required hospitalization.

84 All patient samples were also serologically precharacterized by IIFT.

85 Panel C comprised serum samples taken before August 2019 from 42 healthy German blood
86 donors (Table 1).

87 Panel D comprised serum samples taken between January and March 2020 from twelve German
88 children (Table 1) positive for IgG against seasonal coronaviruses (e.g. HCoV 229-E) by indirect
89 immunofluorescence testing (IIFT, for research use only).

90

91 Detection of anti-SARS-CoV-2 antibodies

92 The detection of the antibodies against SARS-CoV-2 (genus: *Betacoronavirus*, family:
93 *Coronaviridae*) using IIFT was performed with anti-IgG-, anti-IgA- and anti-IgM-FITC-labelled
94 secondary antibodies on infected Vero E6 cells fixed in acetone-methanol^{16,17}. Sample dilutions
95 from 1:20 to 1:80 were screened. In case of a positive result, it was titrated to the final titer. An
96 immunofluorescence signal at titers $\geq 1:20$ was rated as positive and otherwise as negative.

97 Samples were further tested for the presence of antibodies against SARS-CoV-2 with five
98 enzyme-linked immunosorbent assays (ELISA, from EUROIMMUN Medizinische
99 Labordiagnostika AG, Luebeck, Germany). All ELISAs apply viral antigens recombinantly
100 expressed in human cells. The Anti-SARS-CoV-2 ELISA (IgG) and Anti-SARS-CoV-2 ELISA (IgA)
101 are based on the S1 domain of the spike protein of SARS-CoV-2 as antigen, including the
102 immunologically relevant receptor binding domain (RBD), to detect anti-SARS-CoV-2 IgG and
103 IgA antibodies, respectively. The Anti-SARS-CoV-2 QuantiVac ELISA (IgG) was used for
104 quantitative detection of anti-SARS-CoV-2 IgG antibodies by means of a 6-point calibration
105 curve. The Anti-SARS-CoV-2 NCP ELISA (IgG) and Anti-SARS-CoV-2 NCP ELISA (IgM) are based
106 on a modified nucleocapsid protein (NCP) as antigen to detect anti-SARS-CoV-2 IgG and IgM
107 antibodies, respectively. ELISA results were evaluated as recommended by the manufacturer.
108 Borderline results were reported but excluded from the subsequent analyses, since they do not
109 allow secure evaluation and are subjected to retesting by means of other diagnostic methods
110 and/or serological investigation of a follow-up sample in laboratory practice.

111 The detection of SARS-CoV-2-specific antibody responses was also investigated with respect to
112 the infection phase. Because the diagnostic window for serological testing opens several days
113 after pathogen contact, only samples taken later than ten dpso were considered. The phases
114 were split in 11-20 dpso (early phase of infection; n samples in panel A: 10, panel B: 19), 21-60
115 dpso (intermediate phase of infection; n samples in panel A: 28, panel B: 3) and >60 dpso (past
116 infection; n samples in panel A: 43, panel B: 6, Table 1).

117 The overall agreement between qualitative results obtained with the Anti-SARS-CoV-2 ELISA
118 (IgG) and Anti-SARS-CoV-2 QuantiVac ELISA (IgG) was calculated, their degree of agreement was
119 quantified using Cohen's κ including borderline results¹⁸, and the statistical association between
120 results was described using Pearson correlation and 95% confidence intervals as determined by
121 Clopper-Pearson interval.

122 RESULTS

123 The sensitivities varied largely between assays (Table 2). The IIFT revealed positive results for
124 anti-SARS-CoV-2 IgG, IgA and IgM antibodies in 94.6%, 72.9% and 65.9% of the patient samples,
125 respectively. The ELISAs detected specific antibodies against S1 IgG and IgA in 75.8% and 80.3%
126 of the patient samples, respectively. Anti-SARS-CoV-2 IgG and IgM antibodies against NCP were
127 detected in 82.0% and 19.8% of the patient samples, respectively. The specificity was 100% by
128 IIFT, Anti-SARS-CoV-2 ELISA (IgG, IgA) and Anti-SARS-CoV-2 NCP ELISA (IgM), while the four
129 remaining assays reached specificities between 92.9% and 97.6%. Cross-reactivities were not
130 observed.

131
132 The sensitivities of IgA and IgM assays were highest in the early phase of infection, while
133 positive results for IgG antibodies occurred most often in the intermediate phase (Table 3,
134 Figure 1).

135 Positive results for anti-SARS-CoV-2 IgG antibodies against S1 reached a peak during the
136 intermediate phase of infection. In contrast, positive results for anti-SARS-CoV-2 IgA antibodies
137 as measured by IIFT showed an initial peak followed by a pronounced decrease after 60 dpso.
138 During the course of infection, the number of positive results for anti-SARS-CoV-2 IgM
139 antibodies dropped as measured both by ELISA and IIFT.

140 In the early phase of infection (11-20 dpso), IgG and IgA antibodies against S1 of SARS-CoV-2
141 were detected in 70.4% and 88.9% of the samples (n=29), respectively, while IgG and IgM
142 antibodies against NCP were detected in 86.2% and 50%, respectively. The IIFT detected SARS-
143 CoV-2 specific IgG, IgA and IgM antibodies in 96.6%, 93.1% and 96.6% of the samples,
144 respectively.

145 In the intermediate phase of infection (21-60 dpso), IgG and IgA antibodies against S1 of SARS-
146 CoV-2 were detected in 93.3% and 82.8% of the samples (n=31), respectively, while IgG and IgM
147 antibodies against NCP were detected in 96.8% and 12.9%, respectively. The IIFT detected
148 specific IgG, IgM and IgA antibodies in 100%, 87.1% and 100%, respectively.

149 In the late phase of infection (>60 dpso), IgG and IgA antibodies against S1 of SARS-CoV-2 were
150 detected in 85.1% and 80.5% of the samples (n=49), respectively, while IgG and IgM antibodies
151 against NCP were detected in 81.4% and 0%, respectively. The IIFT detected specific IgG, IgA
152 and IgM antibodies in 98%, 44.9% and 30.6%, respectively.

153 Overall, in samples taken later than 10 dpso, IgG and IgA antibodies against S1 of SARS-CoV-2
154 were detected in 83.7% and 83.5% of the samples (n=109), respectively, while IgG and IgM
155 antibodies against NCP were detected in 87.4% and 17%, respectively. The IIFT detected specific
156 IgG, IgA and IgM antibodies in 98.2%, 73.4% and 64.2%, respectively.

157
158 The Anti-SARS-CoV-2 QuantiVac ELISA (IgG) showed a high total agreement (98.9%, Table 4), an
159 almost perfect degree of agreement ($\kappa=0.93$, 95% confidence interval: [0.87, 0.98]) of qualitative
160 results with the Anti-SARS-CoV-2 ELISA (IgG) as well as a high correlation ($r=0.98$, $p<0.001$)
161 between (semi)quantitative results (Figure 2).

162 DISCUSSION

163 The aim of this research was to study long-term kinetics of antibodies against SARS-CoV-2 and to
164 assess the characteristic features of different serological methods. We present findings of the
165 temporal profiles of IgG, IgA and IgM antibody responses against SARS-CoV-2 determined in sera
166 from patients with mild to severe COVID-19 by means of eight serological assays.

167 The sensitivities varied between assays and phases of infection but corroborated that the
168 different substrates used in the assays serve different purposes. Due to the use of the whole
169 SARS-CoV-2 as substrate and the precharacterization by IIFT, the IgG IIFT showed, overall, the
170 highest sensitivity (94.6%) when testing all patient samples, independent of the infection phase
171 (Table 1).

172 The ELISAs, in contrast, provide information about the prevalence of specific antibodies against
173 selected antigens of SARS-CoV-2. Hence, lower sensitivities of the S1-specific ELISAs compared
174 to the NCP-specific ELISA probably reflect the known fact that not all infected individuals
175 produce antibodies against the S1 domain of SARS-CoV-2¹⁰. Importantly, previous research
176 showed that responses of specific IgG against S1 and NCP may be heterogeneous between
177 individuals, time-delayed and do not always coincide with each other^{8,12,14}. In the present panels,
178 the prevalence of specific IgG antibodies against NCP in the early phase of infection was higher
179 than that against S1 (Table 2). However, the findings of the current study do not support
180 previous research by Herroelen et al who undertook a comparative evaluation of commercial
181 SARS-CoV-2 serological assays and observed no clear differences in the seroconversion kinetics
182 of antibodies targeting SARS-CoV-2 S and N protein epitopes between severe and milder SARS-
183 CoV-2 infections.

184 Exclusively in the early phase of infection, the prevalence of specific IgA antibodies against S1
185 was higher than that of specific IgG antibodies against NCP as well as S1. This observation
186 reflects that of Okba et al¹. However, it is contrary to a previous study that showed a higher
187 sensitivity of the Anti-SARS-CoV-2 IgG compared to the Anti-SARS-CoV-2 IgA ELISA in patient
188 samples taken later than fourteen dpso¹⁹, whereby the discrepancy might be due to
189 heterogeneous definitions regarding the early phase of infection.

190 The IgA IIFT showed a pronounced decrease in the antibody detection rate after 60 dpso, which
191 was not observed for the IgA ELISA (Table 2). A possible explanation for this might be that the
192 IgA antibody response against the S1 protein largely remains constant, while the production of
193 IgA antibodies against other antigens of SARS-CoV-2 decreases.

194 More patients were seropositive for IgM by IIFT than by ELISA (Table 1, Table 2), which could be
195 accounted for by a low sensitivity of the NCP IgM ELISA, warranting further investigations.
196 However, the continuously low sensitivity of the NCP-specific IgM ELISA (Table 2) is in
197 accordance with previous results indicating a sensitivity of 55% at week three to four after
198 disease onset²⁰. Liu et al also observed a higher sensitivity of an ELISA based on the spike
199 protein compared to an NCP-based ELISA for detection of IgM antibodies⁸. Two months after
200 symptom onset, we observed a decline in the sensitivity of both IgM-specific assays (Table 2).
201 Independent of the serological method, the two IgM-specific assays reached maximal
202 sensitivities between 11-20 dpso (Table 2) and could therefore especially be applied to detect
203 antibodies in samples taken during the early phase of infection. If patients develop specific IgM
204 against NCP, these antibodies seem to be present for only a short time during the early phase of
205 infection. A sharp decline in the IgM prevalence is to be expected because isotype switching of
206 virus-specific B-cells from IgM to IgG antibody production causes a decline in circulating IgM²¹.
207 The facts that SARS-CoV-2-specific IgM is detected mostly in the early infection phase but only in

208 rare cases²² invites the question whether all isotypes should be measured during
209 serodiagnostics.

210
211 The agreement analysis revealed a very high correlation between results obtained with the Anti-
212 SARS-CoV-2 ELISA (IgG) and the QuantiVac ELISA (IgG). The two samples that showed
213 inconsistent qualitative results between these assays (Table 3, Figure 2) were taken relatively
214 early and late (7 and 116 dpso) in the course of the disease. An explanation for these
215 inconsistencies might be that the assays were incubated using the same aliquot but on different
216 days, hence the experimental conditions might have differed slightly. Another reason might be
217 that the artificial division between positive and negative results does not match the natural
218 range of activity of some samples.

219
220 In general, the use of cells infected with the whole SARS-CoV-2 as substrate has the great
221 advantage of obtaining a high sensitivity due to presence of the complete antigenic spectrum, as
222 evident in the present IIFT results. This is, however, linked to the disadvantage that a positive
223 IIFT result does not allow for a conclusion on the molecular identity of the antigen(s) binding the
224 antibody. In contrast, recombinant cell substrates used in the ELISA technique are ideally suited
225 for the detection and precise identification of antibodies against selected proteins of SARS-CoV-2
226 such as S1/RBD and NCP. During the purification required for Anti-SARS-CoV-2 NCP ELISA
227 production, tertiary or quaternary structured epitopes are often destroyed or weakened.
228 Nevertheless, a selective loss of reactivity does have advantages, since undesired antibody
229 binding aside from the recombinant target protein can be suppressed. Thereby, the specificity of
230 the ELISA can be improved, which was evident in the present results. Moreover, the ELISA
231 technique has the advantage of yielding results in numeral form, which allows an objective
232 evaluation of results. The use of SARS-CoV-2 IIFT is (currently) reserved for specialized research
233 laboratories with high biosafety restrictions due to the handling of the full virus, and, compared
234 to other serological techniques, IIFT is less implemented in standard diagnostic laboratories.

235
236 The presence of anti-SARS-CoV-2 S1/RBD IgG antibodies seems to correlate with the
237 development of both virus neutralization and immunity^{1,3,23}. Previous research found that titers
238 of neutralizing antibodies were significantly correlated with the levels of anti-RBD IgG¹², and
239 RBD-specific IgG titers were suggested as a surrogate of neutralization potency against SARS-
240 CoV-2 infection²⁴. Nevertheless, it is possible that a patient does not develop antibodies against
241 S1 of SARS-CoV-2, but only against NCP. However, this would suggest that neutralizing
242 antibodies might not be present since binding antibodies against NCP seem to correlate to a
243 lesser degree with immunity than binding antibodies against S1/RBD²⁵. The development of
244 immunity to SARS-CoV-2 is induced both by the humoral and the cellular immune response,
245 whereby especially IgG directed against the S1 subunit of the SARS-CoV-2 spike protein and
246 specific long-lived T cells are of great interest, as they are suspected to play the most relevant
247 roles in virus neutralization and sustained immunity. A combination of serological tests to
248 quantify both the interferon-gamma release by SARS-CoV-2-specific T cells, stimulated by SARS-
249 CoV-2 specific antigens, and the presence of anti-S1/RBD IgG antibodies will enable
250 differentiated investigation of the immune response in the progression of infection and
251 vaccination. Especially the determination of relevant antibody concentrations will probably be
252 one of the most important instruments for determining the vaccination success, although it is yet
253 unknown how many antibodies against S1/RBD an individual must produce after vaccination to
254 be protected from COVID-19. Surrogate neutralization assays detect circulating neutralizing

255 antibodies against SARS-CoV-2 that block the interaction between the RBD of SARS-CoV-2 with
256 the ACE2-cell surface receptor of the human host cell, thus supporting a quick diagnostic
257 statement about the degree of immunity. In contrast to plaque-reduction neutralization tests,
258 which require handling of the virus, surrogate neutralization assays can easily be integrated in
259 the laboratory routine and do not require biosafety level 3 laboratories.

260
261 A detailed analysis of potential associations between antibody kinetics and disease severity was
262 not performed because symptoms were not systematically recorded and the disease severity
263 could therefore not be rated other than that patients in panel A had no or mild symptoms and
264 patients in panel B required hospitalization. Nevertheless, the assay sensitivities were reported
265 also for each panel separately (Table 1). Analysis of temporal profiles was performed on samples
266 from both patient panels because the distribution of samples in the three infection phases was
267 unbalanced between panels A and B (Table 1).

268 ELISA or immunoblot techniques might be used in future to differentiate between reactivities
269 against distinctive SARS-CoV-2 antigens, which might be useful for determination of biomarkers
270 indicative of early or late infection phases.

271
272 In summary, evidence of this study emphasizes that the assays have different advantages as well
273 as intended purposes. ELISAs provide an insight into the prevalences of specific antibodies
274 against selected antigens of SARS-CoV-2. Due to the heterogeneity of individual antibody
275 responses, ELISA may not yield positive results for all patients but a combination of ELISAs with
276 different antigens can reduce this diagnostic gap. The three Anti-SARS-CoV-2 ELISAs that detect
277 IgG antibodies can be used to confirm pathogen contact, starting from week two of the infection,
278 to monitor the humoral response following an acute infection confirmed by direct detection and
279 to detect past infections. The highly immunogenic S1 domain of the spike protein of SARS-CoV-2
280 is a major target for neutralizing antibodies and showed good correlation with different test
281 systems for the detection of neutralizing antibodies^{19,26,27}. IgA-specific ELISAs might further be
282 used to monitor the immune response in COVID-19 patients. IIFT showed highest sensitivities
283 due to the use of the whole SARS-CoV-2 as substrate and provide information whether or not an
284 individual has been infected with SARS-CoV-2.

285 **Conflict of Interest**

286 BM, CM, VBL, KS are employees of EUROIMMUN Medizinische Labordiagnostika AG, a company
287 that commercializes serological assays and co-owns a patent application related to
288 immunoassays for the diagnosis of a SARS-CoV-2 infection.

289

290 **Funding**

291 PE and CD received funding from the German Federal Ministry of Education and Research (grant
292 number: 01KI20210). The funder had no role in study design, data collection and analysis,
293 decision to publish, or preparation of the manuscript.

294

295 **Ethics Statement**

296 The observational study has been performed in agreement with the Declaration of Helsinki. It
297 has been approved by the Ethics Review Board of the University Medicine Rostock (registration
298 number: A2020-0086) and the Ethics Review Board of the Medical Association Hamburg
299 (registration number: 2020-10162-BO-ff).

300 The samples from healthy adults (panel C, Table 1) were collected via blood donation. Diagnostic
301 leftover samples after completion of all diagnostic measures from children (panel D, Table 1)
302 were collected by a routine clinical laboratory (Lübeck, Germany). All samples were processed
303 anonymously.

304

305 **Acknowledgements**

306 The authors thank Neele Pekarek of BNITM for supporting performance of the analyses at the
307 facilities of the BNITM.

308 The authors thank Marieke Schulz of EUROIMMUN Medizinische Labordiagnostika AG for
309 supporting laboratory analysis, which was funded by EUROIMMUN Medizinische
310 Labordiagnostika AG, Luebeck, Germany, in accordance with Good Publication Practice (GPP3)
311 guidelines (<http://www.ismpp.org/gpp3>).

312 All probands and patients are gratefully acknowledged for providing samples and participating
313 in this study.

314

315 **Author contributions:**

316 Petra Emmerich: Conceptualization, Investigation, Funding Acquisition, Project Administration,
317 Writing - Review & Editing

318 Ronald von Possel: Investigation, Review & Editing

319 Christoph Hemmer: Investigation, Data curation, Review & Editing

320 Hilte Geerdes-Fenge: Investigation, Data curation, Review & Editing

321 Carlos Fritzsche: Investigation, Data curation, Review & editing

322 Babett Menge: Investigation, Data curation, Writing - Review & Editing

323 Claudia Messing: Resources, Writing - Review & Editing

324 Viola Borchardt-Lohölter: Formal analysis, Visualization, Writing - Original Draft Preparation

325 Christina Deschermeier: Funding Acquisition, Project Administration, Review & Editing

326 Katja Steinhagen: Resources, Project Administration, Writing - Review & Editing

327 REFERENCES

- 328 1. Okba NMA, Müller MA, Li W, et al. Severe Acute Respiratory Syndrome Coronavirus 2 -
329 Specific Antibody Responses in Coronavirus Disease 2019 Patients. *Emerg Infect Dis.*
330 2020;26(7). doi:10.3201/eid2607.200841
- 331 2. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients
332 with COVID-2019. *Nature.* 2020;581(7809):465-469. doi:10.1038/s41586-020-2196-x
- 333 3. To KKW, Tsang OTY, Leung WS, et al. Temporal profiles of viral load in posterior
334 oropharyngeal saliva samples and serum antibody responses during infection by SARS-
335 CoV-2: an observational cohort study. *Lancet Infect Dis.* 2020;20(5):565-574.
336 doi:10.1016/S1473-3099(20)30196-1
- 337 4. Prévost J, Gasser R, Beaudoin-Bussièrès G, et al. Cross-Sectional Evaluation of Humoral
338 Responses against SARS-CoV-2 Spike. *Cell reports Med.* 2020;1(7):100126.
339 doi:10.1016/j.xcrm.2020.100126
- 340 5. Seow J, Graham C, Merrick B, et al. Longitudinal observation and decline of neutralizing
341 antibody responses in the three months following SARS-CoV-2 infection in humans. *Nat*
342 *Microbiol.* 2020;5:1598–1607. doi:10.1038/s41564-020-00813-8
- 343 6. Lippi G, Salvagno GL, Pegoraro M, et al. Assessment of immune response to SARS-CoV-2
344 with fully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence
345 immunoassays. *Clin Chem Lab Med.* 2020;58(7):1156-1159. doi:10.1515/cclm-2020-0473
- 346 7. Long Q-X, Liu B-Z, Deng H-J, et al. Antibody responses to SARS-CoV-2 in patients with
347 COVID-19. *Nat Med.* 2020;26(6):845-848. doi:10.1038/s41591-020-0897-1
- 348 8. Liu W, Liu L, Kou G, et al. Evaluation of Nucleocapsid and Spike Protein-based ELISAs for
349 detecting antibodies against SARS-CoV-2. *J Clin Microbiol.* March 2020.
350 doi:10.1128/JCM.00461-20
- 351 9. Guo L, Ren L, Yang S, et al. Profiling Early Humoral Response to Diagnose Novel
352 Coronavirus Disease (COVID-19). *Clin Infect Dis.* March 2020. doi:10.1093/cid/ciaa310
- 353 10. Oved K, Olmer L, Shemer-Avni Y, et al. Multi-center nationwide comparison of seven
354 serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation.
355 *EClinicalMedicine.* 2020;29-30. doi:10.1016/j.eclinm.2020.100651
- 356 11. Theel ES, Slev P, Wheeler S, Couturier MR, Wong SJ, Kadkhoda K. The Role of Antibody
357 Testing for SARS-CoV-2: Is There One? *J Clin Microbiol.* 2020;(April):1-7.
358 doi:10.1128/JCM.00797-20
- 359 12. Ripperger TJ, Uhrlaub JL, Watanabe M, et al. Orthogonal SARS-CoV-2 Serological Assays
360 Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral
361 Immunity. *Immunity.* 2020;53(5):925-933.e4. doi:10.1016/j.immuni.2020.10.004
- 362 13. Che X, Qiu L, Pan Y, et al. Sensitive and Specific Monoclonal Antibody-Based Capture
363 Enzyme Immunoassay for Detection of Nucleocapsid Antigen in Sera from Patients with
364 Severe Acute Respiratory Syndrome. *J Clin Microbiol.* 2004;42(6):2629 LP - 2635.
365 doi:10.1128/JCM.42.6.2629-2635.2004
- 366 14. McAndrews KM, Dowlathshahi DP, Dai J, et al. Heterogeneous antibodies against SARS-
367 CoV-2 spike receptor binding domain and nucleocapsid with implications on COVID-19
368 immunity. *JCI Insight.* 2020;5(18):1-14. doi:10.1172/jci.insight.142386
- 369 15. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by

- 370 real-time RT-PCR. *Euro Surveill.* 2020;25(3):1-8. doi:10.2807/1560-
371 7917.ES.2020.25.3.2000045
- 372 16. Reisinger EC, von Possel R, Warnke P, et al. Mütter-Screening in einem COVID-19-Niedrig-
373 Pandemiegebiet: Bestimmung SARS-CoV-2-spezifischer Antikörper bei 401 Rostocker
374 Müttern mittels ELISA und Immunfluoreszenz-Bestätigungstest. *Dtsch Medizinische*
375 *Wochenschrift.* 2020. doi:10.1055/a-1197-4293
- 376 17. Emmerich P, Murawski C, von Possel R, et al. Limited specificity of commercially available
377 SARS-CoV-2 IgG ELISAs in serum samples of African origin. *Trop Med Int Heal.* 2020.
378 doi:<https://doi.org/10.1111/tmi.13569>
- 379 18. Watson PF, Petrie A. Method agreement analysis: A review of correct methodology.
380 *Theriogenology.* 2010;73(9):1167-1179. doi:10.1016/j.theriogenology.2010.01.003
- 381 19. GeurtsvanKessel CH, Okba NMA, Igloi Z, et al. Towards the next phase: evaluation of
382 serological assays for diagnostics and exposure assessment. *medRxiv.*
383 2020:2020.04.23.20077156. doi:10.1101/2020.04.23.20077156
- 384 20. Orth-Höller D, Eigentler A, Stiasny K, Weseslindtner L, Möst J. Kinetics of SARS-CoV-2
385 specific antibodies (IgM, IgA, IgG) in non-hospitalized patients four months following
386 infection. *J Infect.* 2020;(xxxx):17-19. doi:10.1016/j.jinf.2020.09.015
- 387 21. Yu HQ, Sun BQ, Fang ZF, et al. Distinct features of SARS-CoV-2-specific IgA response in
388 COVID-19 patients. *Eur Respir J.* 2020;56(2):7-10. doi:10.1183/13993003.01526-2020
- 389 22. Sterlin D, Mathian A, Miyara M, et al. IgA dominates the early neutralizing antibody
390 response to SARS-CoV-2. *Sci Transl Med.* 2021;13(577):eabd2223.
391 doi:10.1126/scitranslmed.abd2223
- 392 23. Weiskopf D, Schmitz KS, Raadsen MP, et al. Phenotype and kinetics of SARS-CoV-2-specific
393 T cells in COVID-19 patients with acute respiratory distress syndrome. *Sci Immunol.*
394 2020;5(48):1-14. doi:10.1126/SCIIMMUNOL.ABD2071
- 395 24. Ni L, Ye F, Cheng ML, et al. Detection of SARS-CoV-2-Specific Humoral and Cellular
396 Immunity in COVID-19 Convalescent Individuals. *Immunity.* 2020;52(6):971-977.e3.
397 doi:10.1016/j.immuni.2020.04.023
- 398 25. McAndrews KM, Dowlatshahi DP, Dai J, et al. Heterogeneous antibodies against SARS-
399 CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19
400 immunity. *JCI Insight.* 2020;5(18):1-14. doi:10.1172/JCI.INSIGHT.142386
- 401 26. Streeck H, Schulte B, Kuemmerer B, et al. Infection fatality rate of SARS-CoV-2 infection in
402 a German community with a super-spreading event. *Nat Commun.*
403 2020;11(5829):2020.05.04.20090076. doi:10.1101/2020.05.04.20090076
- 404 27. Harvala H, Mehew J, Robb ML, et al. Convalescent plasma treatment for SARS-CoV-2
405 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020. *Euro*
406 *Surveill.* 2020;25(28). doi:10.2807/1560-7917.ES.2020.25.28.2001260

407 **TABLES**

408 **Table 1:** Descriptive information of all panels. Dpso: days after symptom onset. Sd: standard
409 deviation.

Panel	Age (mean±sd)	Sex (n females, n males, n unknown)	N samples in panel	N samples per patient (mean±sd, range)	Dpso (mean±sd, range)	N samples ≤10 dpso	N samples 11-20 dpso	N samples 21-60 dpso	N samples >60 dpso
A 25 patients	43.2±13.7,	17, 8, 0	82	3.3±1, [1, 5]	78.4±49.7, [10, 178]	1	10	28	43
B 17 patients	68.0±16.1,	9, 9, 0	47	2.8±1.4, [1, 6]	26.1±30.8, [1, 109]	13	19	3	6
C 42 blood donors	>18, 42 unknown	0, 0, 42	42	1±0	-	-	-	-	-
D 12 children	7.8±4.2, 0 unknown	3, 7, 0	12	1±0	-	-	-	-	-

410

411

412 **Table 2: Diagnostic performance of the assays.** Sensitivities were determined based on panel
413 A (n samples = 82), panels B (n samples = 47) and panels A+B (n samples = 129). Specificities
414 were determined based on panel C (n samples = 42). Cross-reactivities were determined based
415 on panel D (n samples = 12). CI: 95% confidence interval. Borderline ELISA results were
416 excluded for calculation of the sensitivity and specificity.

Panel		HFT			ELISA				
		IgG	IgA	IgM	S1 IgG	QuantiVac S1 IgG	S1 IgA	NCP IgG	NCP IgM
A	n positive	82	59	45	66	66	60	65	4
	n borderline	-	-	-	4	5	10	6	3
	n negative	0	23	37	12	11	12	11	75
	Sensitivity CI [%]	100% [95.6, 100]	72% [60.9, 81.3]	54.9% [43.5, 65.9]	84.6% [74.7, 91.8]	85.7% [75.9, 92.7]	83.3% [72.7, 91.1]	85.5% [75.6, 92.6]	5% [1.4, 12.5]
B	n positive	40	35	40	28	30	34	35	21
	n borderline	-	-	-	1	0	2	1	0
	n negative	7	12	7	18	17	11	11	26
	Sensitivity CI [%]	85.1% [71.7, 93.8]	74.5% [59.7, 86.1]	85.11% [71.7, 93.8]	60.9% [45.3, 74.9]	63.8% [48.5, 77.3]	75.6% [60.5, 87.1]	76.1% [61.2, 87.4]	44.7% [30.2, 59.9]
A+B	n positive	122	94	85	94	96	94	100	25
	n borderline	-	-	-	5	5	12	7	3
	n negative	7	35	44	30	28	23	22	101
	Sensitivity CI [%]	94.6% [89.1, 97.8]	72.9% [64.3, 80.3]	65.9% [57.0, 74.0]	75.8% [67.3, 83.0]	77.4% [69.0, 84.4]	80.34% [72.0, 87.1]	82.0% [74.0, 88.3]	19.8% [13.3, 27.9]
C	n positive	0	0	0	0	1	0	1	0
	n borderline	-	-	-	1	0	1	1	0
	n negative	42	42	42	41	41	41	40	42
	Specificity CI [%]	100% [91.6, 100]	100% [91.6, 100]	100% [91.6, 100]	100% [91.4, 100]	97.6% [87.4, 99.9]	100% [91.4, 100]	97.6% [87.4, 99.9]	100% [91.6, 100]
D	n positive	0	0	0	0	0	0	0	0
	n borderline	-	-	-	0	0	0	0	0
	n negative	12	12	12	12	12	12	12	12
	Cross-reactivity	none	none	none	none	none	none	none	none

417

418 **Table 3:** Number of positive results and sensitivity (%) per infection phase based on 109 serum
 419 samples from panels A+B taken later than ten days after onset of symptoms (dpso). For ELISA,
 420 the number of borderline results are reported in brackets but were excluded for calculation of
 421 the sensitivity.

Phase [dpso]	N samples	IIFT						ELISA									
		IgG		IgA		IgM		S1 IgG		QuantiVac S1 IgG		S1 IgA		NCP IgG		NCP IgM	
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
11-20	29	28	96.6	27	93.1	28	96.6	19 (2)	70.4	20 (1)	71.4	24 (2)	88.9	25 (0)	86.2	14 (1)	50.0
21-60	31	31	100	31	100	27	87.1	28 (1)	93.3	28 (1)	93.3	24 (2)	82.8	30 (0)	96.8	4 (0)	12.9
>60	49	48	98.0	22	44.9	15	30.6	40 (2)	85.1	40 (3)	87.0	33 (8)	80.5	35 (6)	81.4	0 (2)	0.0
≥11	109	107	98.2	80	73.4	70	64.2	87 (5)	83.7	88 (5)	84.6	81 (12)	83.5	90 (6)	87.4	18 (3)	17.0

422

423


424 **Table 4:** Agreement between qualitative results of Anti-SARS-CoV-2 ELISA (IgG) and Anti-SARS-
 425 CoV-2 QuantiVac ELISA (IgG) based on 183 serum samples (panels A, B, C and D).

n samples = 183		Anti-SARS-CoV-2 ELISA (IgG)		
		positive	borderline	negative
Anti-SARS-CoV-2 QuantiVac ELISA (IgG)	positive	93	3	1
	borderline	0	3	2
	negative	1	0	80
Positive agreement		98.9%		
Negative agreement		98.8%		
Total agreement		98.9%		


426

427

428 **FIGURES**
429



430 **Figure 1:** Longitudinal detection of SARS-CoV-2-specific antibody responses in serum samples
431 from panel A (25 patients, 82 samples) and B (17 patients, 47 samples, results of six samples
432 with unknown dpso are not displayed) with respect to phase of infection. Dpso: days after onset
433 of symptoms.
434



435 **Figure 2:** Correlation between semiquantitative results of Anti-SARS-CoV-2 ELISA (IgG) and
436 Anti-SARS-CoV-2 QuantiVac ELISA (IgG).
437